Compare · FRLN vs GILD
FRLN vs GILD
Side-by-side comparison of Freeline Therapeutics Holdings plc (FRLN) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRLN and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $179.56B, about 1538.4x FRLN ($116.7M).
- GILD has hit the wire 11 times in the past 4 weeks while FRLN has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 6 for FRLN).
- Company
- Freeline Therapeutics Holdings plc
- Gilead Sciences Inc.
- Price
- $6.43+0.31%
- $144.81-0.57%
- Market cap
- $116.7M
- $179.56B
- 1M return
- -
- +6.69%
- 1Y return
- -
- +22.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 1992
- News (4w)
- 0
- 11
- Recent ratings
- 6
- 25
Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest FRLN
- Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- SEC Form 15-12G filed by Freeline Therapeutics Holdings plc
- SEC Form EFFECT filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc
- SEC Form POS AM filed by Freeline Therapeutics Holdings plc
- SEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)
- SEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)
Latest GILD
- Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
- Chairman & CEO O'Day Daniel Patrick sold $2,229,592 worth of shares (15,000 units at $148.64) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 577,133 units (SEC Form 4)
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC
- Director Welters Anthony exercised 18,000 shares at a strike of $61.06 and sold $2,675,220 worth of shares (18,000 units at $148.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form N-PX filed by Gilead Sciences Inc.
- Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)